Drug Trial Radar · NCT06524544
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Dec 2, 2025
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
Conditions
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
DocetaxelDrug
Given IV
GemcitabineDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
PaclitaxelDrug
Given IV
PembrolizumabBiological
Given IV
Questionnaire AdministrationOther
Ancillary studies
Sacituzumab GovitecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From randomization to death due to any cause, assessed up to 5 years
Locations
163 sites in 1 country. Site status is shown where the registry gives one.
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Crossroads Cancer Center
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Carle BroMenn Medical Center
Normal, Illinois · Recruiting
Carle Cancer Institute Normal
Normal, Illinois · Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois · Recruiting
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Springfield Memorial Hospital
Springfield, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
McFarland Clinic - Boone
Boone, Iowa · Suspended
Mercy Hospital
Cedar Rapids, Iowa · Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa · Recruiting
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa · Recruiting
McFarland Clinic - Jefferson
Jefferson, Iowa · Suspended
McFarland Clinic - Marshalltown
Marshalltown, Iowa · Recruiting
HaysMed
Hays, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
Lawrence Memorial Hospital
Lawrence, Kansas · Recruiting
The University of Kansas Cancer Center - Olathe
Olathe, Kansas · Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas · Recruiting
Salina Regional Health Center
Salina, Kansas · Recruiting
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.